Cardiometabolic & kidney

Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial

LancetPublished global, phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre, event-driven, cardiovascular safety trial

Primary result · Composite of death from cardiovascular causes, non-fatal stroke, non-fatal myocardial infarction, ischaemia-related coronary revascularisation, or heart failure eventResult — go to the resultHazard ratio 0.89 95% CI 0.67–1.18

Authors' conclusion

In participants with obesity with established cardiovascular disease or chronic kidney disease or at increased risk of cardiovascular disease, survodutide was not associated with increased risk for the primary composite endpoint of death from cardiovascular causes, non-fatal stroke, non-fatal myocardial infarction, ischaemia-related coronary revascularisation, or heart failure event compared with placebo. This cardiovascular safety trial provides clinicians with reassuring data that treatment with survodutide, a novel glucagon receptor-GLP-1 receptor dual agonist, is not associated with increased cardiovascular risk.

Study context

Population
Adults aged 18 years or older with a BMI of 27 kg/m² or greater and established cardiovascular disease or at least two obesity complications or risk factors for cardiovascular disease; participants with chronic kidney disease eligible if BMI of 30 kg/m² or greaterrandomly assigned, 5507 treated (23 not treated)
Participants
5,530 adults
Comparison
Pooled survodutide compared with placebo
  • Survodutide 3.6 mgn = 1,836
  • Survodutide 6.0 mgn = 1,835
  • Survodutide (pooled)n = 3,671
  • Placebon = 1,836reference
Primary endpoint
Composite of:
  • Death from cardiovascular causes
  • Non-fatal stroke
  • Non-fatal myocardial infarction
  • Ischaemia-related coronary revascularisation
  • Heart failure event
Methodological details524 clinical sites in 34 countries, non-inferiority margin 1.65 for the upper limit of the two-sided 95% CI of the HR, treatment-regimen estimand
  • 524 clinical sites in 34 countries
  • Non-inferiority margin 1.65 for the upper limit of the two-sided 95% CI of the HR
  • Treatment-regimen estimand

Primary result

As reported in the abstract

Composite of death from cardiovascular causes, non-fatal stroke, non-fatal myocardial infarction, ischaemia-related…

Hazard ratio

0.89

95% CI 0.67–1.18

P < 0.0001 for non-inferiority

Events by treatment group

Survodutide (pooled)vs placebo
HR 0.89 (95% CI 0.67–1.18); P < 0.0001 for non-inferiority

Further findings

OutcomeSurvodutide 3.6 mgSurvodutide 6.0 mgPlacebo
Remained on treatment until study closeout56.0%56.6%59.0%

Time in study

Median time in study
22.0 months (IQR 20.1-23.7)

Safety

OutcomeSurvodutide 3.6 mgSurvodutide 6.0 mgPlacebo
Adverse events93.0%93.1%85.6%
Nausea48.0%49.0%12.1%
Vomiting31.7%34.0%4.8%
Gastrointestinal adverse events leading to treatment discontinuation19.3%20.8%1.9%
Serious adverse eventsSimilar rates across treatment groups22.5%20.8%23.9%
Fatal adverse eventsSimilar across treatment groups0.9%0.9%0.6%
Fatal adverse events due to cardiac disorders0.3%0.4%0.3%
  • Nausea: Gastrointestinal adverse events were more frequent with survodutide than in the placebo group

Original publication

Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. Published 9 November 2026. doi:10.1016/s0140-6736(26)02140-9

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.